Moore, F D <br/><br/>
The systemic complement activation caused by interleukin-2/lymphokine-activated killer-cell therapy of cancer causes minimal systemic neutrophil activation.  [electronic resource] 

 -  International journal of cancer  Oct 1991 
 - 504-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0020-7136 
<br/><br/><label>Standard No.: </label>10.1002/ijc.2910490405  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Chemotaxis, Leukocyte--drug effects<br/>Complement Activation--drug effects<br/>Complement System Proteins--analysis<br/>Humans<br/>In Vitro Techniques<br/>Interleukin-2--therapeutic use<br/>Killer Cells, Lymphokine-Activated<br/>N-Formylmethionine Leucyl-Phenylalanine--pharmacology<br/>Neoplasms--blood<br/>Neutrophils--drug effects<br/>Treatment Outcome